SAN DIEGO----Ligand Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration has granted accelerated approval of GlaxoSmithKlineâ??s PROMACTA® for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
This entry was posted
on Thursday, January 1st, 1970 at 12:00 am and is filed under Uncategorized.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
